We focus on developing therapies against targets where existing preclinical and early clinical data is available. This data can give a strong indication that a therapy will disrupt a targeted biochemical process and improve patient outcome without significant side-effects. Sareum’s approach is lower risk than developing therapies against entirely novel targets.
Sareum's most advanced development programme (Chk1) is completing the second of two Phase 2 clinical trials, being conducted by licence partner Sierra Oncology, with a further two trials planned. The other development programmes (TYK2/JAK1 Autoimmune, TYK2/JAK1 Cancer, FLT3+Aurora) are in preclinical development.